Cramer's 'Mad Money' Recap: A Clear Cigna to Buy

Volcano's Worth the Leap

Volcano (VOLC Quote) is a great nonpharma medical device stock that's also a play on the drug-coated-stent controversy, said Cramer. There's debate on the safety of such stents, which are used to unclog arteries.

Because Volcano is a small stock, Cramer urged viewers to use limit orders and preferably to not buy the stock until next week. Cramer said he considers Volcano a defensive stock because people don't stop getting health treatment even if the economy is bad.

Volcano makes intravascular ultrasound catheters, which are used to examine the inside of arteries, he said. Although this IVUS technology has been around for years, it has been underutilized, Cramer continued. But because of the controversy regarding stents, the need for checking out the inside of arteries has increased.

Moreover, Volcano's biggest competitor is Boston Scientific (BSX Quote), which Cramer called the Citigroup (C Quote) of health care.

Volcano also has terrific partners, such as Johnson & Johnson (JNJ Quote), which Cramer owns for his Action Alerts PLUS charitable trust, and General Electric (GE Quote).